 The first national negotiation for cancer drugs in China has been successful in reducing the prices of two targeted anti-cancer medicines, TAMS, iCotinib and Gefitinib. This has led to increased usage of these drugs, as well as a decrease in the costs of both drugs. Further price negotiations are needed to ensure that more medicines with clinical benefits are included in reimbursement schemes, so that patients can have better access to essential treatments. This article was authored by Tsong Huang, Carolina Ong, Hei Shuerjieng Wushour and others.